These results suggested that TRPM2 plays a critical role in the progression and metastasis of KIRC, which was consistent with previous research studies showing that TRPM2 affects tumor growth and invasion and is correlated with poor prognosis in patients with breast, gastric, pancreatic, prostate, and head and neck cancers, melanoma, and neuroblastoma (Belrose and Jackson, 2018). Here, TRPM2 is linked to neoplasm.